Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
wrong, you said
First of all, we don't have and don't know how long until we have the full rights if ever, so let's not count those chickens yet.
Secondly, it would double our licensing revenue (profit share) and not our manufacturing revenue, and most of our revenue is from manufacturing fees. Try all that math again.
that's what he said. Sungen has money flow problems bc of all the China issues the last few years (not just covid)
there you go. Nasrat tried to secure it for Elite and it didn't work out. Boom. Nasrat was looking out for Elite.
I would rather Mikah take on the loan than us.
We will hit $7m this quarter and expects same for next qtr.
Going concern is removed
how would we, Elite, have financed it? No thanks on loans or dilution.
How much less can an investor care
more like give me back what I loaned you or pay me 20%.
and apparently 24 hr old non uploaded conference call audio
that would be mean we already hit dollar land. Let's do it.
disappointing is a vague, objective word. Wanna be more specific, maybe offer a number? a range? $5m? $6m? $7m? Some might say $10m would be great while others might say it's disappointing.
I for one would never invest in or stay invested in a company in which I thought the ceo is a trickster. but that's just one of my silly investing rules.
we might get some "preliminary" numbers. might not get any. Nasrat might just say we're close to the next cc, let's just wait until we have the full financials worked out. Suppose Nasrat makes some microscopically small mistake bc he was estimating or going off the top of his head. pitchforks will be out until he can fix it during the next cc.
lol
happens every quarter. investors get their hopes up about some sure thing. It doesn't come through. then it's back to off with Nasrat's head.
lmao
probably also a good idea to let the company set the dates
rotfl
delayed implies there was some official expectation of timing. the cc wasn't til the 24th last year. I see no reason to label this as a delay.
I don't like to count chickens before they hatch. we're at least many months from having a marketable generic concerta. And we're clearly having a problem with its development.
but even still, how many publicly traded companies have been bought for the rights to 2 generic drugs?
not sure what "buyout" has to do with the topic at hand but buyout for what? we have nothing anyone would want or give a premium for. We have only one good generic and there are other approved anda of xr not being used. They could get those cheaper.
Do you not believe Nasrat when he says
We didn't need additional authorized shares; the problem was the pps staying below .10 stopped us from selling shares to Lincoln. Also remember the going concern can only be removed as part of a full audit, which we only do once annually thus far. That is surely already finished. regardless, xr should negate the gc as said.
what kind of bounce would that be? just want to make sure I've got my terminology correct.
seems like Nasrat would be better off keeping the preferred shares instead of "getting" his. If an investor want to "punish" Nasrat, he/she should probably vote yes.
dang it. I hate when Elite goes up. bounce. bounce.
These words are not the words of a man who expects to "cash in soon" or sees a buyout looming. If we're going to trust Nasrat on some things, we should also trust him on these things.
Nasrat has given every indication that he plans to be around for a long time yet. If an investor is going to put value into any of Nasrat's words, then an investor should put value into all of his words, and Nasrats words clearly indicate that he has no intention of selling any time soon, which he specifically said about his shares.
share price is often a lagging indicator or else there would be no such thing as value investing.
are you saying that information says they've discontinued the Activis version of XR also? Is that the "current stock" you are referencing?
so is it speculation or misinformation? lol el oh el
I wouldn't read into that too much. Their data entry person probably isn't allowed to put DEA cut drug quota (probably not a pre-selected option), nor is the person likely to understand supply and demand.
it's funny how those expectations change every second, often every millisecond.
do go on please. I would just love to hear more about this theory.
if LCI is on "suicide watch", wouldn't anything that might get LCI off "suicide watch" be something to do with Elite since we are relying on them to distribute our most important products to ALL the states?
I'm afraid I'm going to need a larger sample size.
sounds like a writer (of the article) trying to be edgy. Lannett still had better than expected revenue, and revenue is what matters for our partnership. Revenue proves they can sell the drugs. Taxes Lannett has to pay do not mean anything for Elite.
Analysts missing proves as much or more about their incompetence as analysts as it does about Lannett's management.
no proof presented. case closed. Nobody said Lannett would distribute XR to 9277 Walgreens in less than 24 hrs.
Elite as related to Lannett Central Nervous System report
Elite Adderall IR approval 7Dec2018*****Lannett quarter CNS 31Dec2018 - $6,187,000
**********************************************Lannett quarter CNS 31Mar2019 - $9,424,000
Lannett launch Adderall IR 16Apr2019 **Lannett quarter CNS 30Jun2019 - $11,362,000
**********************************************Lannett quarter CNS 30Sep2019 - $19,257,000
Elite Adderall XR approval 12Dec2019***Lannett quarter CNS 31Dec2019 - $19,331,000
Lannett launch Adderall XR 31Mar2020**Lannett quarter CNS 31Mar2020 - $18,566,000
Interesting to see Lannetts growth with CNS as related to Elites approval and launch.
I believe Jan-Mar 2020 was good $$ for Elite's Adderall IR and maybe a couple of $$ for XR.
The really big money for IR and XR will show when Elite reports 1st QTR results in August 2020.
AND GROW EXPONENTIALLY EVERY FUTURE QUARTER!!!
Jan-Mar was F*ed up for every business so don't read too much into it. Elite is still operating and making $millions
Credit to ARbigguy1
hello, Lannett just received the XR product at the very end of that quarter. The very end. Did anyone say or imply Lannett would sell billions of XR in less than 24 hours?
not really bc it's a complete moot point. Lannett had no opportunity to distribute generic Adderall XR for last quarter, therefore no opportunity to make money from it. All the talk of Lannett's financials last quarter is meaningless for the Elite lannett partnership. Let's give them more than a single day for XR.
We shipped and booked the XR manufacturing fees at the very end of the quarter. Lannett didn't have time to sell the frickin medicine yet. all that matters is we booked the profits. Our quarter will be just fine, and don't forget Lannett is distributing to all the states, not just three.
thanks, However, I think it's safe to say, the "monster" will certainly make us tens of million a year, which will be a monster for us, though it was only meant as sarcasm.
Here's the "nice DD", everyone. Good god almighty. shaking our heads, alright. the monster is back on. market share is back on. blockbuster distribution partnership is back on.
We are a US-based company, with our headquarters in Philadelphia, PA, and top-notch facilities for research and development, manufacturing, packaging, business, and distribution in three states including Pennsylvania, Indiana, and New York
"facilities..........in three states........."
read it again bc that's not what it says or means. the statement is about employees and facilities, not distribution locales.